Analysts Set McKesson Corporation (NYSE:MCK) Price Target at $962.67

Shares of McKesson Corporation (NYSE:MCK) have received a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $962.6667.

MCK has been the topic of several analyst reports. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. UBS Group increased their price objective on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wells Fargo & Company lowered their price objective on McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $875.00 target price on shares of McKesson in a research note on Friday, May 8th. Finally, TD Cowen reduced their target price on McKesson from $1,012.00 to $989.00 and set a “buy” rating on the stock in a research report on Tuesday, July 21st.

McKesson Stock Performance

NYSE:MCK opened at $857.61 on Friday. McKesson has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The stock has a market capitalization of $100.41 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.42 and a beta of 0.31. The company’s 50-day simple moving average is $790.71 and its 200-day simple moving average is $840.22.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The firm had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same quarter in the previous year, the business posted $10.12 EPS. McKesson’s revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, research analysts forecast that McKesson will post 44.28 EPS for the current year.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, September 1st. This is a positive change from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s payout ratio is presently 8.53%.

Insider Activity at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total value of $6,715,898.28. Following the completion of the transaction, the chief executive officer directly owned 5,919 shares of the company’s stock, valued at $4,697,081.64. This trade represents a 58.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 28,748 shares of company stock worth $22,262,035. 0.06% of the stock is owned by insiders.

Institutional Investors Weigh In On McKesson

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Horizon Investments LLC lifted its stake in McKesson by 125.4% during the 4th quarter. Horizon Investments LLC now owns 8,679 shares of the company’s stock valued at $7,119,000 after acquiring an additional 4,828 shares during the period. Northstar Advisory Group LLC boosted its holdings in shares of McKesson by 133.4% in the 4th quarter. Northstar Advisory Group LLC now owns 3,704 shares of the company’s stock valued at $3,038,000 after acquiring an additional 2,117 shares during the last quarter. J. Safra Sarasin Holding AG acquired a new stake in shares of McKesson in the fourth quarter worth $2,481,000. Mn Services Vermogensbeheer B.V. increased its stake in shares of McKesson by 2.8% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 48,721 shares of the company’s stock worth $39,965,000 after acquiring an additional 1,321 shares during the period. Finally, James Hambro & Partners LLP acquired a new stake in shares of McKesson in the fourth quarter worth $99,181,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson’s compounding growth remains the primary bullish catalyst. The company delivered strong fiscal 2026 results, raised its outlook, increased its dividend and expanded share repurchases. Its distribution and specialty-pharmaceutical businesses continue to generate substantial free cash flow, which may appeal to investors favoring defensive, cash-rich companies. McKesson’s Compounding Keeps Adding Up
• Neutral Sentiment: Wall Street is focused on estimates for McKesson’s quarter ended June 2026, including operating metrics beyond revenue and earnings. The estimates could influence expectations for the company’s upcoming report, but the article does not identify a new earnings surprise or change in guidance. Curious about McKesson Q1 Performance?
• Neutral Sentiment: Recent market commentary highlights a rotation toward defensive stocks as investors respond to inflation, geopolitical tension and uncertainty over interest rates. McKesson’s healthcare-distribution model and free-cash-flow generation could benefit from that trend, although the broader market backdrop remains unsettled. McKesson’s Compounding Keeps Adding Up
• Negative Sentiment: The latest reported quarter offered a mixed signal: adjusted earnings exceeded expectations, but revenue fell short of consensus despite year-over-year growth. That result, combined with a valuation near 22 times earnings and the absence of a fresh company-specific catalyst, may be encouraging profit-taking after the stock’s strong advance.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.